Antithrombotic Therapy in ASCVD + VTE: AQUATIC - Prof. Behnood Bikdeli, Prof. Romain Didier https://t.co/tl55cc228t @bbikdeli

VALIANT: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN by Drs. Fakhouri, Nester et al. https://t.co/7hAAF7jMhf Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 GN or primary immune-complex MPGN.

Trends in CVE & Bleeding in Advanced CKD: SRR - Dr. M. Evans, Dr. A.-L. Faucon (Stockholm, Sweden) https://t.co/Seb5eyJYtB

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease by Drs. Bartholdy, @TorBiering et al. https://t.co/Wu8i8w2o6H In this prespecified analysis of DANFLU-2 a benefit of HD-IIV over SD-IIV was observed.

Extended DOAC Therapy in Provoked VTE - HI-PRO - Prof. Behnood Bikdeli, Prof. Romain Didier @bbikdeli https://t.co/dKbR8p50q4

Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD) by Drs. @niklasdj1, @TorBiering et al. https://t.co/gK0jxbWIT4 In this analysis, HD-IIV demonstrated superior protection compared with SD-IIV.

Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects by Drs. @mayocvonc, @joshmitchellmd et al. An International Cardio-Oncology Society Position Statement: https://t.co/efX2eH93p0

Deferring Arterial Catheterization in Critically Ill Patients with Shock by Drs. Muller, Boulain et al. https://t.co/Mg25vYpXeB Results for death from any cause at day 28 indicated that management without early arterial cath. insertion was noninferior to early cath. insertion.

Couldn't be there live? No problem, here are the highlights! Kongressupdate AHA / ASN 2025 https://t.co/58dj1GsYog @ASNKidney @American_Heart

A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: LIBERATE-D by Drs. Liu, Hsu et al. https://t.co/QEry4PQ5pV A conservative dialysis strategy promoted recovery from dialysis-requiring acute kidney injury.

What an exciting weekend... So many new studies to discuss!

ESC Dyslipidemia Guidelines - 2025 Update - Prof. Dr. François Mach, Geneva, Switzerland https://t.co/tcGCbvmHcp Prof. Mach presents the 2025 Focused Update of the European Guidelines for the management of dyslipidaemias, which have been published by @escardio @society_eas .

Rituximab for Relapsing Nephrotic Syndrome in Adults by Drs. Isaka, Hiromura et al. https://t.co/YF1w8Xo1gj The relapse-free rate at week 49 was 87.4%(95% CI, 69.8%-95.1%) in the rituximab group and 38.0%(95% CI, 22.1%-53.8%) in the placebo group.

Short-Term Anticoagulation versus DAPT for Preventing Device Thrombosis Following LAAC: The ANDES RCT by Drs. Rodés-Cabau, Salaun et al. https://t.co/fh27TdLtF6 The use of DOAC after LAAC failed to reduce DRT compared to DAPT but it was associated with an improved safety profile.

Stream it now! Our webinar in cooperation with NDT: IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan @IgAN_JBarratt @jradnephro @NDTsocial @AKronbichler @gunnar_heine @hjanders_hans https://t.co/zzkhNkE4CP

Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury The BICARICU-2 Randomized Clinical Trial by Drs. @borisjung34, @JABERSamir3 et al. https://t.co/quB1qN1nQz In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.

Urinary tract infection and continuation of SGLT-I in diabetic patients by Drs. Wu, Yiu et al. https://t.co/7biA8ITpdU Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.

Our experts explain: CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall , Prof. Halbritter, Prof. @MuellerRom https://t.co/vxLZsuJuGG They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. @ronfvv, Zhang et al. https://t.co/tDKXoSCcUx The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.

Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK) https://t.co/F8MXRSRLKe Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.